Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

作者
Paolo Tarantino,Stefania Morganti,Giuseppe Curigliano
出处
期刊:Exploration of targeted anti-tumor therapy [Open Exploration Publishing]
卷期号:2 (2): 139-155 被引量:27
标识
DOI:10.37349/etat.2021.00037
摘要

About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene. Such alterations lead to a more aggressive behavior of the disease, but also predict response to treatments targeting HER2. Indeed, several anti-HER2 compounds have been developed and approved in the last two decades, significantly improving our ability to cure patients in the early setting, and greatly extending their survival in the advanced setting. However, recent evolutions in this field promise to improve outcomes even further, through advancements in established HER2-targeting strategies, as well as the exploration of novel strategies. In particular, the engineering of new antibody-drug conjugates, with higher drug-to-antibody ratios (DARs) and cleavable linkers, has already led to the development of a highly effective drug, namely trastuzumab deruxtecan, recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of advanced HER2-positive (HER2+) BC, and currently in study in the early setting. Moreover, the novel tyrosine kinase inhibitor tucatinib was recently approved by FDA and EMA, showing to improve survival of HER2+ advanced BC patients, particularly in those with brain metastasis. Immunotherapy is also being investigated in the HER2+ subtype, through immune-checkpoint inhibition, cancer vaccines and adoptive-cell therapies. Overall, the enlarging arsenal of promising anti-HER2 compounds is expected to deliver significant improvements in the prognosis of both early and advanced HER2+ BC in the years to come. Moreover, some of such agents are showing encouraging activity in the much wider population of HER2-low advanced BC patients, challenging current BC classifications. If confirmed, this new paradigm would potentially expand the population deriving benefit from HER2-targeted treatments to up to 70% of all advanced BC patients, leading to a revolution in current treatment algorithms, and possibly to a redefinition of HER2 classification.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cdercder的应助被等待书桃采纳,获得10
刚刚
ShengZonghao完成签到,获得积分20
1秒前
1秒前
1秒前
1秒前
姬鲁宁完成签到 ,获得积分10
1秒前
迷人渊思完成签到,获得积分10
2秒前
云澈完成签到,获得积分10
2秒前
bkagyin的应助被mj采纳,获得10
2秒前
碳酸盐完成签到,获得积分10
2秒前
2秒前
3秒前
Code_king发布了新的文献求助10
3秒前
甜咸完成签到,获得积分20
3秒前
3秒前
韩书琴完成签到 ,获得积分10
4秒前
cdercder的应助被杉杉采纳,获得10
4秒前
XIOOYU发布了新的文献求助10
5秒前
lwj关闭了lwj的文献求助
6秒前
盒子发布了新的文献求助50
6秒前
武玉蕊完成签到,获得积分10
7秒前
7秒前
8秒前
8秒前
acc完成签到,获得积分10
8秒前
完美世界的应助被哈哈小妖怪采纳,获得10
9秒前
10秒前
Fei发布了新的文献求助10
10秒前
10秒前
11秒前
11秒前
无情的聪健的应助被当归采纳,获得20
12秒前
12秒前
wanci的应助被zora采纳,获得10
12秒前
万能图书馆的应助被方卓采纳,获得10
13秒前
13秒前
江北第一深情完成签到 ,获得积分10
13秒前
李国涛发布了新的文献求助10
13秒前
水煮电吹风的应助被parantal采纳,获得30
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177404
求助须知:如何正确求助?哪些是违规求助? 9568297
关于积分的说明 21798595
捐赠科研通 7772027
什么是DOI,文献DOI怎么找? 3432346
关于科研通互助平台的介绍 2556564
邀请新用户注册赠送积分活动 2477863